Connect Biopharma Presents Phase 2 Data Showing Rademikibart Cuts COPD Treatment Failures by 81%

PUBT · 2d ago
Connect Biopharma Presents Phase 2 Data Showing Rademikibart Cuts COPD Treatment Failures by 81%
  • Connect Biopharma plans FDA talks in December 2026 on Phase 3 acute asthma development, prioritizing asthma for its projected faster approval path.
  • Rademikibart reduced treatment failure by 81% versus placebo through four weeks in the Phase 2 acute COPD trial (p=0.0122).
  • The COPD trial showed 85% fewer new moderate-to-severe exacerbations (p=0.0301); emergency department visits and hospital admissions for exacerbations fell 100% (p=0.0137).
  • In acute asthma, treatment failure fell 66% versus placebo by Day 28, though the result was not statistically significant (p=0.153).
  • Post-bronchodilator lung function improved by 130 milliliters versus placebo at Day 7 in the asthma trial (p=0.023).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.